Universal Ibogaine Announces First Closing of Private Placement Financing

NOTFOR DISSEMINATION IN THE UNITED STATES
OR THROUGH U.S. NEWS WIRES

                             

 

 

 

NEWS RELEASE

UNIVERSAL IBOGAINEINC. ANNOUNCES
INITIAL CLOSING OF PRIVATE PLACEMENT FINANCING

November 25, 2020

Vancouver, British Columbia - Universal Ibogaine Inc. (“UI” or the “Company”)is pleased to advise that it has completed a first closing of $2.3 million under its current private placement offering of $0.25 Units (the “Offering”),with the following highlights:

·       a total of 9,369,392 Units have been issued with a value of $2,342,348

·       the Units issued under the Offeringconsist of one UI common share and one warrant to purchase an additional UI common share (the “Warrants”).  

·       the Warrants will have a 5-year term to expiry,and an escalating annual exercise price (increasing by $0.25 per year, startingat $0.50 if exercised in year 1, to $1.50 if exercised in year 5).

This initial closing includes Units issued for cash received to November 20, 2020 and Units issued in settlement of services received and certain obligations owing by the Company.  In addition, UI will issue a minimum of $500,000 of Units as partial consideration payable on closing of the pending acquisition of the Kelburn Clinic (as described further below).

                                                                                                                               

The above total of $774,499 includes Units valued at $306,667 which were issued for the value of past services received from members of UI’s Board ofDirectors.  

Additional subscription agreements have been received under the Offering, and UI will process a further closing in the next two weeks for additional cash proceeds in processof being received.

Shayne Nyquvest, UI Chairman and Founder, noted “We are excited by the level ofinterest we have received for the Offering – this financing gives us financial flexibility to achieve our short-term objectives, and build on our momentum heading into our Prospectus offering and RTO go-public transaction.”

Following issuance of the above noted 9,369,392 Units, UI will have approximately 92.5million common shares issued and outstanding. In addition, UI is obligated to issue i) a total of 30 million common shares for issuance under a 2019 Licensing Agreement with Clear Sky Recovery Cancun SA de CV (“Clear Sky”), ii) 2 million common shares for the Kelburn Clinic acquisitionand iii) approximately 10 million common shares to be issued to certain UI shareholders on completion of the upcoming RTO “liquidity event”.  The Clear Sky shares are to be issued onclosing of the RTO / merger with PSQ (see below) with their release subject to UI achieving various future performance milestones related to the Licensing Agreement with Clear Sky.

Pending Acquisition by UI of the Kelburn Clinic

UI previously entered into a letter of intent with an arms-length party to acquire the operations of an addiction treatment facility near Winnipeg, Manitoba, the Kelburn Mental Health & Addiction Recovery Centre (the "Kelburn Clinic").  The Kelburn Clinic is privately owned and has been in operation for 6 years.  UI is in process of finalizing a purchase agreement, and intends to close the funding of this acquisition no later than closing of the RTO and related Prospectus (described further below).

It is intended that consideration payable for the Kelburn Clinic acquisition will consist of $1 million cash and a minimum of $500,000 equity requested by the owners of the property, payable in the form of 2,000,000 UI Units (which willhave the same terms as those being issued under the current Offering).

The Kelburn Clinic site is operated under a long-term lease of the premises from certain of its related party shareholders. UI intends to initially acquire solely the operations of the KelburnClinic, and lease the related land and building (with a two-year option to subsequently acquire those assets). Further, UI intends to expand the operations and optimize and improve Kelburn’shistorical occupancy.

Planned RTO and Go-public Transaction

On October 7, 2020, UI finalized an Amalgamation Agreement for the proposed business combination / merger with P Squared Renewables Inc. ("PSQ"),a capital pool company listed (TSXV: PSQ.P) on the TSX Venture Exchange (the “TSXV”).

The merger with UI, the related prospectus financing (described below), and UI’s pending acquisition of the Kelburn Clinic are intended to constitute PSQ’s“Qualifying Transaction” (the “QT”) pursuant to the requirements of the TSXV.

Forfurther details, please refer to PSQ’s prior news release of October 9, 2020,the highlights of which are summarized as:

·       The merger with PSQ will result in areverse take-over (“RTO”) of PSQ by UI.

·       PSQ plans to conduct a prospectusoffering of units closing concurrently with the QT, for gross proceeds of a minimum of $3 million and a maximum of up to $5 million (the “Prospectus”).  It is intended that the units issued under the Prospectus will be comprised of one common share and one-half of one common share purchase warrant.

PSQ and UI have submitted a preliminary Prospectus to the TSXV for review, and are in process of forming a syndicate of investment bankers who will market this financing.

Significant Conditions to Completion of the QT

Completion of the QT is subject to a number of conditions, including but not limited to: (i) the ‎conditions stipulated in the Amalgamation Agreement (including completion of the Prospectus Offering); (ii) closing conditions customary to‎ transactions of the nature of the QT; (iii) the approval of UI's shareholders; and (iv) the ‎approval of applicable regulatory bodies in connection with the QT, including but not limited to ‎the TSXV.

About Universal Ibogaine Inc.

UI is a privately held company formed in 2018 and based in Vancouver, BC.  UI is in the initial stages of implementing and financing its business plan, which is to develop a network of global ibogaine assisted psycho-therapy clinics for the treatment and ideally the cure of addictions to primarily opioids, as well as alcohol, cocaine, heroin, fentanyl and other stimulants.

UI plans to submit a Clinical Trial Application (the “CTA”)to Health Canada to undertake clinical trials in Canada to prove the efficacy of the use of ibogaine, a natural substance, in the treatment of polysubstance addictions including opioids.  In the longer term, UI plans to introduce ibogaine into the addiction treatment protocols to be used in its future facilities.

UIalso holds a 20 acre property on an island near San Pedro, Belize, and is reviewing the concept of having a joint venture partner finance and develop a potential future resort or after-care facility on this site.

About PSQ

PSQ was incorporated in 2017 and listed on the TSXV (as a Capital Pool Company) on June 21, 2017 under the trading symbol "PSQ.P".  Since its formation, PSQ has been searching for and evaluating suitable business combinations to constitute its QT under the policies of the TSXV.

PSQis a "reporting issuer" in the provinces of Alberta and British Columbia and currently has 11,560,850 common shares outstanding and option sexercisable or exchangeable for a total of 1,150,000 common shares, exercisable at an exercise price of $0.10 per share.

Further Information

Completion of the QT is subject to a number of conditions, including but not limited to,TSXV acceptance.  There can be noassurance that the QT will be completed as proposed or at all.  

Investors are cautioned that, except as disclosed in the Prospectus to be prepared in connection with the Prospectus Offering and the related QT, any information released or received with respect to the transactions may not be accurate or complete and should not be relied upon.

An investment in the securities of the Company should be considered highly speculative.  

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to: UI’s financing and business plans; the terms and conditions of the planned Prospectus Offering; UI’s pending acquisition of the Facility; the completion of the QT (including the Amalgamation contemplated thereby); and the business and operations of the combined company “Resulting Issuer” after the QT.

Words such as "will", "expects", "anticipates", "intends", "plans", "believes", "estimates", or similar expressions identify forward-looking statements.  Such forward-looking statements reflect the current beliefs of UI’s management, based on information currently available to them.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; delay or failure to receive applicable Board, shareholder or regulatory approvals.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

For further information, please contact:  

Jeremy Weate                                                                Shayne Nyquvest

Chief Executive Officer                                                   Chairman

Universal Ibogaine Inc.                                                   Universal Ibogaine Inc.

Telephone: __                                                                Telephone:604-512-9541

Email: jeremy@ibogaineinc.com

 

Don't miss these stories: